Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

NCT04262856 is registered in ClinicalTrials.gov with Arcus Biosciences, Inc. as lead sponsor.

NCT NCT04262856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04262856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Lead sponsor
Arcus Biosciences, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 28, 2020
Completion date
July 9, 2025
Enrollment
151 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non small cell lung cancer, nonsquamous non small cell lung cancer, squamous non small cell lung cancer